News
Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...
Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh® is an interleukin-23p19 ...
1d
Zacks Investment Research on MSNEli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...
8d
Zacks Investment Research on MSNLilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending Eli Lilly’s Omvoh ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results